The acquisition also included the SENSEI radio-guided surgery business, which will integrate into Telix and operate as a new surgeon-focused business unit. Credit: ABRAHAM POPOCATL on Unsplash.

Australia-based Telix Pharmaceuticals has signed an agreement to acquire UK-based Lightpoint Medical along with its SENSEI radio-guided surgery business.

The purchase price consists of an upfront equity payment of A$29m ($20m) and a further earn-out payment of A$22m ($15m) in cash or equity, after attaining certain milestones linked to the ongoing development and commercialisation of the SENSEI probe.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Designed for intracavitary use, SENSEI is an ultra-miniature robotic gamma probe that facilitates intra-operative cancer detection in real time to offer radiopharmaceutical-based surgical guidance (radio-guided surgery).

Set to be integrated into Telix, the Lightpoint SENSEI business will operate as a new surgeon-focused business unit.

In addition, this new unit will support the development of other related medical devices and software technologies of Telix.

Lightpoint also has artificial intelligence (AI) capabilities for surgical guidance, which will complement the AI programme of Telix.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The acquisition is expected to strengthen Telix’s capabilities in implementing molecular imaging in the surgical setting.

Lightpoint Medical founder and CEO Dr David Tuch said: “This acquisition brings numerous benefits to our surgeon users including enhanced access to the SENSEI technology and a continuum of PSMA-based detection and treatment options.”

SENSEI secured marketing authorisation from the US Food and Drug Administration in September 2020.

In January 2021, it also received the CE mark for use in the European Economic Area and other applicable countries for intra-operative identification of sentinel lymph nodes and cancer metastasis through the lymphatic system.

In addition, SENSEI is claimed to be the only gamma probe validated for use with the Intuitive Surgical DaVinci robotics system.

Telix first signed a strategic partnership agreement with Lightpoint in August 2021 for the joint development of SENSEI with its PSMA-targeting SPECT imaging agent TLX599-CDx for prostate cancer.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact